United States Biotechnology & Medical Research

Soleno Therapeutics Inc (SLNO)

Track

The most recent insider trading activity at Soleno Therapeutics Inc. occurred on March 27, 2026. On this date, Chief Commercial Officer Meredith Manning and Sr. VP of Clinical Development Michael F. Huang executed multiple sales of company shares. These transactions represent the latest recorded insider activity for the firm.
Ticker: SLNO Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Soleno Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
194.88
Quantity 15,603 -5.8%
Value US$3,713,763
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
443.89
Quantity 38,892 -14.3%
Value US$1,520,880
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
397.10
Quantity 8,206 +6.1%
Value US$2,795,936
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
31.72
Quantity 488 -1.2%
Value US$15,479
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
31.04
Quantity 1,838 -4.4%
Value US$57,049
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
30.04
Quantity 4,256 -9.2%
Value US$127,837
Abingworth Bioventures VII LP Shareholder
Transaction date
Proposed sale
Price
82.15
Quantity 1,347,522
Value US$110,696,581
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
82.76
Quantity 3,830 -22.5%
Value US$316,971
2.0
PATRICIA HIRANO Officer Officer
Transaction date
Proposed sale
Price
82.76
Quantity 3,830
Value US$316,971
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
84.25
Quantity 266 -1.5%
Value US$22,410
2.0
PATRICIA HIRANO Officer Officer
Transaction date
Proposed sale
Price
84.25
Quantity 266
Value US$22,410
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
70.11
Quantity 3,782 -12.3%
Value US$265,156
2.0
PATRICIA HIRANO Officer Officer
Transaction date
Proposed sale
Price
70.11
Quantity 3,782
Value US$265,156
2.8
Pauls Matthew Non-Executive Director
Transaction date
Sale
Price
71.55
Quantity 5,937 -47.7%
Value US$424,797
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
73.60
Quantity 2,691 -8.0%
Value US$198,058
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
69.52
Quantity 9,253 -21.6%
Value US$643,246
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
68.92
Quantity 12,324 -22.4%
Value US$849,386
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
67.46
Quantity 3,394 -5.8%
Value US$228,946
2.0
PATRICIA HIRANO Officer Officer
Transaction date
Proposed sale
Price
69.40
Quantity 27,662
Value US$1,919,636
2.8
Matthew Pauls Officer Officer
Transaction date
Proposed sale
Price
67.39
Quantity 5,937
Value US$400,094
2.9
Vivo Opportunity, LLC Large shareholder
Transaction date
Sale
Price
70.60
Quantity 333,557 -7.0%
Value US$23,549,124
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
67.04
Quantity 37,000 -44.9%
Value US$2,480,436
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
72.64
Quantity 34 -0.1%
Value US$2,470
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
71.74
Quantity 225 -0.5%
Value US$16,142
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
70.73
Quantity 155 -0.3%
Value US$10,964
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
69.84
Quantity 1,505 -3.2%
Value US$105,105
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
68.79
Quantity 2,599 -5.2%
Value US$178,780
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
67.70
Quantity 1,976 -3.8%
Value US$133,777
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
66.79
Quantity 1,087 -2.1%
Value US$72,602
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
65.97
Quantity 668 -1.2%
Value US$44,067
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
70.80
Quantity 8,044 -7.1%
Value US$569,494
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
70.03
Quantity 36,157 -24.2%
Value US$2,531,919
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
69.07
Quantity 25,799 -14.7%
Value US$1,782,022
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
72.64
Quantity 86 -0.1%
Value US$6,247
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
71.74
Quantity 563 -0.5%
Value US$40,391
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
70.73
Quantity 387 -0.4%
Value US$27,374
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
69.84
Quantity 3,762 -3.4%
Value US$262,727
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
68.79
Quantity 6,498 -5.6%
Value US$446,985
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
67.70
Quantity 4,940 -4.1%
Value US$334,441
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
66.79
Quantity 2,717 -2.2%
Value US$181,473
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
65.97
Quantity 1,669 -1.3%
Value US$110,102
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
66.95
Quantity 23,475 -45.5%
Value US$1,571,717
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
66.00
Quantity 50,156 -49.3%
Value US$3,310,080
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
72.64
Quantity 91 -0.1%
Value US$6,610
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
71.74
Quantity 597 -1.0%
Value US$42,831
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
70.73
Quantity 411 -0.7%
Value US$29,072
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
69.84
Quantity 3,990 -6.0%
Value US$278,650
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
68.79
Quantity 6,891 -9.4%
Value US$474,019
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
67.70
Quantity 5,239 -6.7%
Value US$354,684
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
66.79
Quantity 2,881 -3.5%
Value US$192,427
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
65.97
Quantity 1,769 -2.1%
Value US$116,699
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
70.03
Quantity 10,000 -21.4%
Value US$700,330
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
72.64
Quantity 19 -0.1%
Value US$1,380
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
71.74
Quantity 125 -0.3%
Value US$8,968
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
70.73
Quantity 86 -0.2%
Value US$6,083
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
69.84
Quantity 836 -2.2%
Value US$58,384
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
68.79
Quantity 1,444 -3.7%
Value US$99,330
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
67.70
Quantity 1,098 -2.7%
Value US$74,335
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
66.79
Quantity 604 -1.5%
Value US$40,342
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
65.97
Quantity 371 -0.9%
Value US$24,475
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
72.50
Quantity 15,145 -21.4%
Value US$1,098,012
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
70.18
Quantity 24,989 -26.1%
Value US$1,753,628
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
67.47
Quantity 24,776 -20.5%
Value US$1,671,629
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
66.39
Quantity 46,214 -27.7%
Value US$3,068,147
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
72.64
Quantity 73 -0.1%
Value US$5,303
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
71.74
Quantity 478 -0.5%
Value US$34,293
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
70.73
Quantity 329 -0.3%
Value US$23,272
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
69.84
Quantity 3,198 -3.2%
Value US$223,339
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
68.79
Quantity 5,524 -5.3%
Value US$379,985
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
67.70
Quantity 4,199 -3.9%
Value US$284,275
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
66.79
Quantity 2,310 -2.1%
Value US$154,289
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
65.97
Quantity 1,418 -1.3%
Value US$93,544
2.1
Anish Bhatnagar CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Sale
Price
69.30
Quantity 199,226 -25.7%
Value US$13,805,904
2.1
Anish Bhatnagar CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Sale
Price
67.37
Quantity 8,423 -1.1%
Value US$567,458
2.1
Anish Bhatnagar CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Sale
Price
66.33
Quantity 209,689 -21.1%
Value US$13,908,797
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-31 2026-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
15,603 -5.8%
194.88
US$3,713,763 		15,603 -5.8% 194.88 US$3,713,763
2026-03-31 2026-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
38,892 -14.3%
443.89
US$1,520,880 		38,892 -14.3% 443.89 US$1,520,880
2026-03-31 2026-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
8,206 +6.1%
397.10
US$2,795,936 		8,206 +6.1% 397.10 US$2,795,936
2026-03-31 2026-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
488 -1.2%
31.72
US$15,479 		488 -1.2% 31.72 US$15,479
2026-03-31 2026-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
1,838 -4.4%
31.04
US$57,049 		1,838 -4.4% 31.04 US$57,049
2026-03-31 2026-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
4,256 -9.2%
30.04
US$127,837 		4,256 -9.2% 30.04 US$127,837
2025-08-15 2025-08-11 PrS Proposed sale
Abingworth Bioventures VII LP

Shareholder
1,347,522
82.15
US$110,696,581 		1,347,522 82.15 US$110,696,581
2025-07-03 2025-07-01 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
3,830 -22.5%
82.76
US$316,971 		3,830 -22.5% 82.76 US$316,971
2025-07-01 2025-07-01 PrS Proposed sale
2.0
PATRICIA HIRANO

Officer

Officer
3,830
82.76
US$316,971 		3,830 82.76 US$316,971
2025-06-26 2025-06-24 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
266 -1.5%
84.25
US$22,410 		266 -1.5% 84.25 US$22,410
2025-06-24 2025-06-24 PrS Proposed sale
2.0
PATRICIA HIRANO

Officer

Officer
266
84.25
US$22,410 		266 84.25 US$22,410
2025-04-02 2025-04-01 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
3,782 -12.3%
70.11
US$265,156 		3,782 -12.3% 70.11 US$265,156
2025-04-01 2025-04-01 PrS Proposed sale
2.0
PATRICIA HIRANO

Officer

Officer
3,782
70.11
US$265,156 		3,782 70.11 US$265,156
2025-03-31 2025-03-28 S Sale
2.8
Pauls Matthew
Non-Executive Director
5,937 -47.7%
71.55
US$424,797 		5,937 -47.7% 71.55 US$424,797
2025-03-31 2025-03-28 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
2,691 -8.0%
73.60
US$198,058 		2,691 -8.0% 73.60 US$198,058
2025-03-31 2025-03-28 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
9,253 -21.6%
69.52
US$643,246 		9,253 -21.6% 69.52 US$643,246
2025-03-31 2025-03-28 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
12,324 -22.4%
68.92
US$849,386 		12,324 -22.4% 68.92 US$849,386
2025-03-31 2025-03-28 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
3,394 -5.8%
67.46
US$228,946 		3,394 -5.8% 67.46 US$228,946
2025-03-28 2025-03-28 PrS Proposed sale
2.0
PATRICIA HIRANO

Officer

Officer
27,662
69.40
US$1,919,636 		27,662 69.40 US$1,919,636
2025-03-28 2025-03-28 PrS Proposed sale
2.8
Matthew Pauls

Officer

Officer
5,937
67.39
US$400,094 		5,937 67.39 US$400,094
2025-03-28 2025-03-28 S Sale
2.9
Vivo Opportunity, LLC
Large shareholder
333,557 -7.0%
70.60
US$23,549,124 		333,557 -7.0% 70.60 US$23,549,124
2025-03-31 2025-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
37,000 -44.9%
67.04
US$2,480,436 		37,000 -44.9% 67.04 US$2,480,436
2025-03-31 2025-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
34 -0.1%
72.64
US$2,470 		34 -0.1% 72.64 US$2,470
2025-03-31 2025-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
225 -0.5%
71.74
US$16,142 		225 -0.5% 71.74 US$16,142
2025-03-31 2025-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
155 -0.3%
70.73
US$10,964 		155 -0.3% 70.73 US$10,964
2025-03-31 2025-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
1,505 -3.2%
69.84
US$105,105 		1,505 -3.2% 69.84 US$105,105
2025-03-31 2025-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
2,599 -5.2%
68.79
US$178,780 		2,599 -5.2% 68.79 US$178,780
2025-03-31 2025-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
1,976 -3.8%
67.70
US$133,777 		1,976 -3.8% 67.70 US$133,777
2025-03-31 2025-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
1,087 -2.1%
66.79
US$72,602 		1,087 -2.1% 66.79 US$72,602
2025-03-31 2025-03-27 S Sale
0.8
Manning Meredith

Chief Commercial Officer

Officer
668 -1.2%
65.97
US$44,067 		668 -1.2% 65.97 US$44,067
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
8,044 -7.1%
70.80
US$569,494 		8,044 -7.1% 70.80 US$569,494
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
36,157 -24.2%
70.03
US$2,531,919 		36,157 -24.2% 70.03 US$2,531,919
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
25,799 -14.7%
69.07
US$1,782,022 		25,799 -14.7% 69.07 US$1,782,022
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
86 -0.1%
72.64
US$6,247 		86 -0.1% 72.64 US$6,247
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
563 -0.5%
71.74
US$40,391 		563 -0.5% 71.74 US$40,391
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
387 -0.4%
70.73
US$27,374 		387 -0.4% 70.73 US$27,374
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
3,762 -3.4%
69.84
US$262,727 		3,762 -3.4% 69.84 US$262,727
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
6,498 -5.6%
68.79
US$446,985 		6,498 -5.6% 68.79 US$446,985
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
4,940 -4.1%
67.70
US$334,441 		4,940 -4.1% 67.70 US$334,441
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
2,717 -2.2%
66.79
US$181,473 		2,717 -2.2% 66.79 US$181,473
2025-03-31 2025-03-27 S Sale
2.5
Mackaness James H

CHIEF FINANCIAL OFFICER

Officer
1,669 -1.3%
65.97
US$110,102 		1,669 -1.3% 65.97 US$110,102
2025-03-31 2025-03-27 S Sale
2.0
Yen Kristen

SEE REMARKS

Officer
23,475 -45.5%
66.95
US$1,571,717 		23,475 -45.5% 66.95 US$1,571,717
2025-03-31 2025-03-27 S Sale
2.0
Yen Kristen

SEE REMARKS

Officer
50,156 -49.3%
66.00
US$3,310,080 		50,156 -49.3% 66.00 US$3,310,080
2025-03-31 2025-03-27 S Sale
2.0
Yen Kristen

SEE REMARKS

Officer
91 -0.1%
72.64
US$6,610 		91 -0.1% 72.64 US$6,610
2025-03-31 2025-03-27 S Sale
2.0
Yen Kristen

SEE REMARKS

Officer
597 -1.0%
71.74
US$42,831 		597 -1.0% 71.74 US$42,831
2025-03-31 2025-03-27 S Sale
2.0
Yen Kristen

SEE REMARKS

Officer
411 -0.7%
70.73
US$29,072 		411 -0.7% 70.73 US$29,072
2025-03-31 2025-03-27 S Sale
2.0
Yen Kristen

SEE REMARKS

Officer
3,990 -6.0%
69.84
US$278,650 		3,990 -6.0% 69.84 US$278,650
2025-03-31 2025-03-27 S Sale
2.0
Yen Kristen

SEE REMARKS

Officer
6,891 -9.4%
68.79
US$474,019 		6,891 -9.4% 68.79 US$474,019
2025-03-31 2025-03-27 S Sale
2.0
Yen Kristen

SEE REMARKS

Officer
5,239 -6.7%
67.70
US$354,684 		5,239 -6.7% 67.70 US$354,684
2025-03-31 2025-03-27 S Sale
2.0
Yen Kristen

SEE REMARKS

Officer
2,881 -3.5%
66.79
US$192,427 		2,881 -3.5% 66.79 US$192,427
2025-03-31 2025-03-27 S Sale
2.0
Yen Kristen

SEE REMARKS

Officer
1,769 -2.1%
65.97
US$116,699 		1,769 -2.1% 65.97 US$116,699
2025-03-31 2025-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
10,000 -21.4%
70.03
US$700,330 		10,000 -21.4% 70.03 US$700,330
2025-03-31 2025-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
19 -0.1%
72.64
US$1,380 		19 -0.1% 72.64 US$1,380
2025-03-31 2025-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
125 -0.3%
71.74
US$8,968 		125 -0.3% 71.74 US$8,968
2025-03-31 2025-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
86 -0.2%
70.73
US$6,083 		86 -0.2% 70.73 US$6,083
2025-03-31 2025-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
836 -2.2%
69.84
US$58,384 		836 -2.2% 69.84 US$58,384
2025-03-31 2025-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
1,444 -3.7%
68.79
US$99,330 		1,444 -3.7% 68.79 US$99,330
2025-03-31 2025-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
1,098 -2.7%
67.70
US$74,335 		1,098 -2.7% 67.70 US$74,335
2025-03-31 2025-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
604 -1.5%
66.79
US$40,342 		604 -1.5% 66.79 US$40,342
2025-03-31 2025-03-27 S Sale
0.7
Huang Michael F.

Sr. VP of Clinical Development

Officer
371 -0.9%
65.97
US$24,475 		371 -0.9% 65.97 US$24,475
2025-03-31 2025-03-27 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
15,145 -21.4%
72.50
US$1,098,012 		15,145 -21.4% 72.50 US$1,098,012
2025-03-31 2025-03-27 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
24,989 -26.1%
70.18
US$1,753,628 		24,989 -26.1% 70.18 US$1,753,628
2025-03-31 2025-03-27 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
24,776 -20.5%
67.47
US$1,671,629 		24,776 -20.5% 67.47 US$1,671,629
2025-03-31 2025-03-27 PlS Planned sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
46,214 -27.7%
66.39
US$3,068,147 		46,214 -27.7% 66.39 US$3,068,147
2025-03-31 2025-03-27 S Sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
73 -0.1%
72.64
US$5,303 		73 -0.1% 72.64 US$5,303
2025-03-31 2025-03-27 S Sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
478 -0.5%
71.74
US$34,293 		478 -0.5% 71.74 US$34,293
2025-03-31 2025-03-27 S Sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
329 -0.3%
70.73
US$23,272 		329 -0.3% 70.73 US$23,272
2025-03-31 2025-03-27 S Sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
3,198 -3.2%
69.84
US$223,339 		3,198 -3.2% 69.84 US$223,339
2025-03-31 2025-03-27 S Sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
5,524 -5.3%
68.79
US$379,985 		5,524 -5.3% 68.79 US$379,985
2025-03-31 2025-03-27 S Sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
4,199 -3.9%
67.70
US$284,275 		4,199 -3.9% 67.70 US$284,275
2025-03-31 2025-03-27 S Sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
2,310 -2.1%
66.79
US$154,289 		2,310 -2.1% 66.79 US$154,289
2025-03-31 2025-03-27 S Sale
2.0
Hirano Patricia C

SEE REMARKS

Officer
1,418 -1.3%
65.97
US$93,544 		1,418 -1.3% 65.97 US$93,544
2025-03-31 2025-03-27 S Sale
2.1
Anish Bhatnagar

CHIEF EXECUTIVE OFFICER

Executive Director
199,226 -25.7%
69.30
US$13,805,904 		199,226 -25.7% 69.30 US$13,805,904
2025-03-31 2025-03-27 S Sale
2.1
Anish Bhatnagar

CHIEF EXECUTIVE OFFICER

Executive Director
8,423 -1.1%
67.37
US$567,458 		8,423 -1.1% 67.37 US$567,458
2025-03-31 2025-03-27 S Sale
2.1
Anish Bhatnagar

CHIEF EXECUTIVE OFFICER

Executive Director
209,689 -21.1%
66.33
US$13,908,797 		209,689 -21.1% 66.33 US$13,908,797
Explore more

More insider trading research around Soleno Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America